These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 25598933)

  • 1. The association of 5-alpha reductase type 2 (SRD5A2) gene polymorphisms with prostate cancer in a Korean population.
    Choi SY; Kim HJ; Cheong HS; Myung SC
    Korean J Urol; 2015 Jan; 56(1):19-30. PubMed ID: 25598933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
    Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
    J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2.
    Loukola A; Chadha M; Penn SG; Rank D; Conti DV; Thompson D; Cicek M; Love B; Bivolarevic V; Yang Q; Jiang Y; Hanzel DK; Dains K; Paris PL; Casey G; Witte JS
    Eur J Hum Genet; 2004 Apr; 12(4):321-32. PubMed ID: 14560315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population.
    Onen IH; Ekmekci A; Eroglu M; Polat F; Biri H
    DNA Cell Biol; 2007 Feb; 26(2):100-7. PubMed ID: 17328668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SRD5A2 gene polymorphisms and the risk of benign prostatic hyperplasia but not prostate cancer.
    Choubey VK; Sankhwar SN; Carlus SJ; Singh AN; Dalela D; Thangaraj K; Rajender S
    Asian Pac J Cancer Prev; 2015; 16(3):1033-6. PubMed ID: 25735326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer.
    Setlur SR; Chen CX; Hossain RR; Ha JS; Van Doren VE; Stenzel B; Steiner E; Oldridge D; Kitabayashi N; Banerjee S; Chen JY; Schäfer G; Horninger W; Lee C; Rubin MA; Klocker H; Demichelis F
    Cancer Epidemiol Biomarkers Prev; 2010 Jan; 19(1):229-39. PubMed ID: 20056642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphism of the SRD5A2 gene and the risk of prostate cancer.
    Dušenka R; Tomaškin R; Kliment J; Dobrota D; Dušenková S; Vilčková M; Sivoňová MK
    Mol Med Rep; 2014 Dec; 10(6):3151-6. PubMed ID: 25310105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SRD5A polymorphisms and biochemical failure after radical prostatectomy.
    Audet-Walsh E; Bellemare J; Nadeau G; Lacombe L; Fradet Y; Fradet V; Huang SP; Bao BY; Douville P; Girard H; Guillemette C; Lévesque E
    Eur Urol; 2011 Dec; 60(6):1226-34. PubMed ID: 21715084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of 5α-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer.
    Lévesque É; Laverdière I; Lacombe L; Caron P; Rouleau M; Turcotte V; Têtu B; Fradet Y; Guillemette C
    Clin Cancer Res; 2014 Feb; 20(3):576-84. PubMed ID: 24277450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).
    Lunn RM; Bell DA; Mohler JL; Taylor JA
    Carcinogenesis; 1999 Sep; 20(9):1727-31. PubMed ID: 10469617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic variations in genes involved in testosterone metabolism are associated with prostate cancer progression: A Spanish multicenter study.
    Henríquez-Hernández LA; Valenciano A; Foro-Arnalot P; Álvarez-Cubero MJ; Cozar JM; Suárez-Novo JF; Castells-Esteve M; Fernández-Gonzalo P; De-Paula-Carranza B; Ferrer M; Guedea F; Sancho-Pardo G; Craven-Bartle J; Ortiz-Gordillo MJ; Cabrera-Roldán P; Rodríguez-Melcón JI; Herrera-Ramos E; Rodríguez-Gallego C; Lara PC
    Urol Oncol; 2015 Jul; 33(7):331.e1-7. PubMed ID: 25960412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer.
    Li X; Huang Y; Fu X; Chen C; Zhang D; Yan L; Xie Y; Mao Y; Li Y
    Mutagenesis; 2011 May; 26(3):371-83. PubMed ID: 21177315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer.
    Chang BL; Zheng SL; Isaacs SD; Turner AR; Bleecker ER; Walsh PC; Meyers DA; Isaacs WB; Xu J
    Prostate; 2003 Jun; 56(1):37-44. PubMed ID: 12746845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.
    Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
    Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):191-6. PubMed ID: 26857022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5alpha-reductase 2 polymorphisms as risk factors in prostate cancer.
    Söderström T; Wadelius M; Andersson SO; Johansson JE; Johansson S; Granath F; Rane A
    Pharmacogenetics; 2002 Jun; 12(4):307-12. PubMed ID: 12042668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.
    Neslund-Dudas C; Bock CH; Monaghan K; Nock NL; Yang JJ; Rundle A; Tang D; Rybicki BA
    Prostate; 2007 Nov; 67(15):1654-63. PubMed ID: 17823934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.
    Yamada Y; Watanabe M; Murata M; Yamanaka M; Kubota Y; Ito H; Katoh T; Kawamura J; Yatani R; Shiraishi T
    Int J Cancer; 2001 Jun; 92(5):683-6. PubMed ID: 11340572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of SRD5A2 gene mutations with risk of hypospadias in the Iranian population.
    Rahimi M; Ghanbari M; Fazeli Z; Rouzrokh M; Omrani S; Mirfakhraie R; Omrani MD
    J Endocrinol Invest; 2017 Apr; 40(4):391-396. PubMed ID: 27848231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
    Hsing AW; Chen C; Chokkalingam AP; Gao YT; Dightman DA; Nguyen HT; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Stanczyk FZ; Reichardt JK
    Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single nucleotide polymorphisms in DKK3 gene are associated with prostate cancer risk and progression.
    Kim MS; Lee HN; Kim HJ; Myung SC
    Int Braz J Urol; 2015; 41(5):869-97. PubMed ID: 26689513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.